Pfizer gives green light to $1.26bn Ireland expansion

Pfizer has announced its largest Irish investment weeks after rumors emerged of an expansion at its Grange Castle biomanufacturing site.

Dan Stanton, Editorial director

December 2, 2022

1 Min Read
Pfizer gives green light to $1.26bn Ireland expansion
Pfizer's Grange Castle site in Dublin, Ireland. Image c/o Google

Pfizer has announced its largest Irish investment weeks after rumors emerged of a €1 billion+ expansion at its Grange Castle, Dublin biomanufacturing site.

In October, the Irish press revealed Pfizer was set to invest €1 billion into the 90-acre manufacturing site in Clondalkin, Dublin. At the time, the Big Pharma firm refused to comment when contacted by this publication.

But six weeks on, and the cat is out of the single-use bag, with Pfizer formalizing the €1.2 ($1.26) billion investment to build a new facility to double the site’s capacity for biological drug substance.

pfizer-ireland-grange-castle-300x167.jpg

Pfizer’s Grange Castle site in Dublin, Ireland. Image c/o Google

Site leader Marius McNicholas described the news as “an historic day today in Pfizer Grange Castle” on LinkedIn, with the investment “Pfizer’s biggest expansion investment to date in Ireland.”

Beyond the doubling of capacity, the expansion will create up 500 roles, he said, bringing the total number of Pfizer employees in Ireland to approximately 5,500.

Ireland’s An Tánaiste Leo Varadkar welcomed the investment, stating: “The pharma sector is such an important part of the Irish economy and the commitment shown by Pfizer to further expand its business here is great news.

“The work undertaken at their facilities across Ireland saves and improves the lives of people all over the world.  I am very pleased that their presence in Dublin, and indeed in Ireland, continues to go from strength to strength.”

The expansion is the latest for Pfizer’s Grange Castle. Last year, the site benefitted from a $40 million mRNA expansion to support the firm’s COVID-19 vaccine efforts.

About the Author

Dan Stanton

Editorial director

Journalist covering the international biopharmaceutical manufacturing and processing industries.
Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like